LWCFA
SGMO

Loring Wolcott & Coolidge Fiduciary Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,000
Closed -$47K – 796
2020
Q3 		$47K Hold
5,000
– – ﹤0.01% 405
2020
Q2 		$45K Hold
5,000
– – ﹤0.01% 386
2020
Q1 		$32K Hold
5,000
– – ﹤0.01% 416
2019
Q4 		$42K Buy
+5,000
New +$46K ﹤0.01% 435

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's SGMO Position: Q4 2020 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2020, closing a stake of 5,000 shares — an estimated $47K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in SGMO in Q4 2019 and held it in 4 quarters. The position peaked at $47K in Q3 2020. 223 funds tracked by Wall St. Rank hold SGMO as of Q4 2020.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2020 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 5,000 SANGAMO THERAPEUTICS INC shares in Q4 2020, an estimated $47K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 4 quarters.
  • Loring Wolcott & Coolidge Fiduciary Advisors's SANGAMO THERAPEUTICS INC position peaked at $47K in Q3 2020.
  • 223 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2020.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2020, filed 14 Jan 2021.